Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share
1. Mura and XOMA Royalty announced an acquisition deal for Mura's shares. 2. Mura shareholders to receive $2.035 base cash per share, with potential for $0.205 more. 3. Acquisition values Mura at approximately $36.2 million, with significant share price premiums. 4. Mura's board endorses deal to maximize shareholder value after strategic review. 5. Deal expected to finalize by end of 2025, pending shareholder approval and court sanction.